Gastro-enterologie - Prof. dr. Len Verbeke

Master Geneeskunde

KU Leuven
Afstudeerjaar: 2008

Master Specialistische Geneeskunde

KU Leuven
Richting: gastro-enterologie
Afstudeerjaar 2016

Doctor Biomedische Wetenschappen

KU Leuven
Afstudeerjaar: 2014

• 2016 - 2018: Staflid en adjunct-kliniekhoofd maag-, darm- en leverziekten (UZ Leuven)
• 2018 - 2019: Docent KU Leuven, professor in de geneeskunde
• 2018 - heden: Arts maag, darm- en leverziekten (AZ Sint-Maarten)
• 2020 - heden: Gastprofessor Universiteit Antwerpen
• 2020 - heden: Consulent interventionele endoscopie (UZ Antwerpen)

• Ziektes van lever, gal en pancreas
• Leververvetting en klinische studies m.b.t. leververvetting
• Gespecialiseerde endoscopische interventies: ERCP, echo-endoscopie en interventionele echo-endoscopie

• Stichtend bestuurslid van de young BASL: De Belgische vereniging voor de studie van leverziekten
• BASL (Belgian Association Study Liver Disease)
• EASL (European Association Study of Liver Disease)

• 2008: Winner of the Professor J. De Groote prize
• 2011: Winner of the Belgian Association for Study of Liver disease (BASL) research grant
• 2012: Winner of the Vlaamse Vereniging voor Gastro-Enterologie (VVGE) research grant
• 2013: Winner of the Belgian Week of Gastroenterology research grant
• 2014: Winner of the BASL award for best oral presentation in basic research, Brussels
• 2014: Winner of the Belgian Week of Gastroenterology award for best oral presentation, Brussels
• 2014: Winner of the best oral abstract in basic science at the EASL international liver congress, London
• 2015: Winner of the Belgian Week of Gastroenterology award for best oral presentation in basic science, Brussels

Verbeke L, De Niel C. Gestegen serumtroponinen in afwezigheid van een acuut coronair syndroom. Tijdschr Geneesk 2008; 64(5):225-231.

Verbeke L, Delforge M, Dierickx D. Current insight into thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2010; 21(1):3-10. IF 1.24.

Laleman W, Verbeke L, Meersseman P, Wauters J, Van Pelt J, Cassiman D et al. Acute-onchronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol. 2011; 5(4):523-37. (Shared first authorship with W. Laleman). IF 2.96.

Verbeke L, Nevens F, Laleman W. Bench-to-bedside-review: Acute-on-chronic liver failure: linking the gut, liver and systemic circulation. Crit Care 2011; 15(5):233. IF 4.95.

Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 2012; 92:1428-1439. IF 4.20.

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144(7): 1426-38. (Verbeke L is a Pubmed-indexed contributor to this paper on behalf of the CANONIC consortium). IF 18.19.

Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S et al. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59(6):2286-98. IF 11.06.

Verbeke L, Trebicka J, Laleman W. Reply: To PMID 24259407. Hepatology 2014; 60(5):1799- 800. IF 11.06.

Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J et al. Obeticholic acid, an FXR agonist, prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015 Feb;185(2):409-19. IF 4.21.

Verbeke L, Laleman W, Nevens F. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Jul 16; 373(3):281. IF 59.56.

Kerbert AJC, Verbeke L, Chiang FWT, Laleman W, van de Reijden JJ, van Duijn W, et al. Copeptin as an indicator of hemodynamic derangement and prognosis in liver cirrhosis. Plos One 2015; 10(9):e0138264. IF 3.54.

Klein S, Rick J, Lehmann J, Schierwagen R, Schierwagen IG, Verbeke L, et al. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut 2017; 66(1):145-155. IF 14.92.

Laleman W, Trebicka J, Verbeke L. Evolving insights in the pathophysiology of complications of cirrhosis: The Farnesoid-X receptor (FXR) to the rescue? Hepatology 2016; 64(5):1792-1794. IF 11.06.

Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Vander Elst I, Windmolders P, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016; 6:33453. IF 5.23.

Ceulemans LJ, Canovai E, Verbeke L, Pirenne J, Farre R. The expanding role of the bile acid receptor farnesoid X in the intestine and its potential clinical implications. Acta Chir Belg. 2016; 10:1-8. IF 0.394.

Ceulemans LJ, Verbeke L (*shared first authorship with Ceulemans LJ), Decuypere JP, Farre R, De Hertogh G, Lenaerts K, et al. Farnesoid-X receptor (FXR) agonist improves survival in a model of intestinal ischemia reperfusion injury by attenuating mucosal integrity, endotoxin translocation, inflammation and authophagy. Plos One 2017; 6;12(1):e0169331. IF 3.54.

Verbeke L, Nevens F, Laleman W. Steroidal or non-steroidal FXR agonists - is that the question? J Hepatol. 2017. IF 11.34.

Laleman W, van der Merwe S, Verbeke L, Vanbeckevoort D, Aerts R, Prenen H, et al. A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study. Endoscopy. 2017; 49(10):977-982. IF 6.63.

Deprez PH, Garces Duran R, Moreels T, Furneri G, Demma F, Verbeke L, et al. The economic impact of using single-operator cholangioscopy for the treatment of difficult bile duct stones and diagnosis of indeterminate bile duct strictures. Endoscopy 2018; 50(2):109-118. IF 6.63.

Francque S, Lanthier N, Verbeke L, Reynaert H, Van Steenkiste C, Vonghia L, et al. The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease. Acta Gastroenterol Belg 2018; 81(1):55-81. IF

Jardinet T, Verbeke L, Bonne L, Maleux G. Therapeutic intranodal lymphangiography for refractory chylous ascites complicating acute necrotic pancreatitis. J Gastrointestin Liver Dis 2018; 27(2):195-197. IF 1.96.

Meelberghs L, Van der Merwe S, Nevens F, Verbeke L, Windmolders P, Vander Elst I. Bacterial translocation during experimental cirrhosis coincidences with the infiltration of inflammatory monocytes in the gut. J Hepatol. 2018; 68, Supplement 1, Page S470. IF 14.9. 

Gilbo N, Jochmans I, Sainz-Barriga M, Nevens F, van der Merwe S, Laleman W, Verslype C, Cassiman D, Verbeke L, et al. Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully Selected. Transplant Direct 2019; 26,5(4).

De Vloo C, Matton T, Meersseman W, Maleux G, Houthoofd S, Op de Beeck K, Laleman W, Van Malenstein H, Nevens F, Verbeke L, et al. Thrombosis of a portal vein aneurysm: a case report with literature review. Acta Clin Belg 2019;74(2): 115-120. IF 1.0.

Bronswijk M, Wildiers H, Verbeke L. Progressive liver dysfunction due to diffuse radio-occult metastatic invasion: a case series illustrating the need for early liver biopsy. [Manuscript submitted]

Verbeke L, Roskams T, Verslype C, Cassiman D, Van Der Merwe S, Van Steenbergen W, et al. Ductular bilirubinostasis predicts the evolution to acute-on-chronic liver failure in patients suspected with severe alcoholic steatohepatitis. [Manuscript in progress] Internationale mondelinge presentaties

Verbeke L. Nodular regenerative hyperplasia of the liver: case presentation. Presented at the 10th Annual Symposium of the Belgian Society of Medical Oncology, Brussels 2008.

Verbeke L. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Presented at the AASLD (American Association for the Study of Liver Diseases) Liver Meeting 2013 in Washington DC on November 4th of 2013.

Verbeke L. Obeticholic acid, a Farnesoid-X Receptor-agonist, reduces bacterial translocation and restores intestinal permeability in a rat model of cholestatic liver disease. Presented at the EASL (European Association for the Study of the Liver) International Liver Congress 2014 (ILC 2014); plenary session in London on April 10th of 2014.

Verbeke L. Refractory hepatic encephalopathy and indications for interventional radiology. Presented together with Wim Laleman at the International Liver Congress 2015 (ILC 2015); in Vienna on April 24h of 2015.

Verbeke L. In toxic cirrhotic rats, the FXR agonist obeticholic acid reduces liver fibrosis via an anti-inflammatory effect in liver sinusoidal endothelial cells and Kupffer cells. Presented at the International Liver Congress 2016 (ILC 2016); in Barcelona on April 14h of 2016. Internationale poster presentaties

Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis by endothelial dysfunction and altered microvascular architecture. Presented at AASLD, Boston, 2011.

Coenraad MJ, Verbeke L, Laleman W, et al. Copeptin as biomarker of systemic hemodynamic derangements in TAA cirrhotic rats. Presented at EASL, Amsterdam, 2013.

Verbeke L, Roskams T, Verslype C. Ductular bilirubinostasis predicts the evolution to acute-onchronic liver failure in patients suspected with severe alcoholic steatohepatitis. Presented at AASLD, Boston, 2014.

Verbeke L, Mannaerts I, Schierwagen R. Obeticholic acid, an FXR agonist, reduces hepatic fibrosis a rat model of toxic cirrhosis. Presented at EASL, Vienna, 2015. Peer reviewed publicaties in medische tekstboeken

Dierickx D, Verbeke L. The use of rituximab in immune-mediated anaemia. In: European Haematology Vol 4 (2010). Published by Touch Briefings. ISSN: 1756-6096.

Laleman W, Verbeke L, Trebicka J, Nevens F. Pathophysiology of acute on chronic liver failure: the good, the bad and the ugly. Therapy in Liver Diseases 2015